Effects of Vincristine in Combination with Methotrexate and Other Antitumor Agents in Human Acute Lymphoblastic Leukemia Cells in Culture

YasuhiKO Kano, Takao Ohnuma, Tsuyoshi Okano, and James F. Holland

Department of Neoplastic Diseases and Cancer Center, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York 10029

ABSTRACT

The effects of vincristine (VCR) in combination with methotrexate (MTX) and other antitumor agents were evaluated by cell growth inhibition assay using a human acute lymphoblastic leukemia cell line (MOLT-3). The data were analyzed with the aid of an isobologram using the concept of an envelope of additivity (G. G. Steel and M. J. Peckman, Int. J. Radiat. Oncol., 5: 85-91, 1979). Simultaneous exposure of VCR and MTX produced subadditive or mutually protective interactions. Sequential exposure to VCR first followed immediately by MTX produced similar interactions. When the interval of VCR exposure first and then MTX was increased from 0 to 3, 8, and 24 h, the inhibition of cell growth moved from protection and subadditivity to additivity only. The reversed order of exposure to the 2 drugs produced an entirely different picture. Thus, when the interval of MTX exposure first followed by VCR increased from 0 to 3, 8, and 24 h, the inhibitory effects of the combination changed progressively from the area of subadditivity to the area of supraadditivity. When these data were evaluated using median effect plot analyses (T-C. Chou and P. Talalay, In: New Avenues in Developmental Cancer Chemotherapy, pp. 36-64. Orlando, FL: Academic Press, 1987), strongly synergistic interaction of this sequence at space intervals was confirmed. These data show that the synergistic effects were produced only when MTX was followed 8 or 24 h later by VCR. Other schedules were only additive or even antagonistic.

Simultaneous exposure of VCR with daunorubicin, 1-β-D-arabinofuranosylcytosine, or bleomycin also had subadditive and protective effects. VCR, followed by daunorubicin with the interval of 24 h and vice versa, was again subadditive and protective. VCR, followed by 1-β-D-arabinofuranosylcytosine with the interval of 24 h and vice versa, was again subadditive or additive only. Simultaneous and continuous exposures of VCR with vinblastine or l-asparaginase were only marginally supraadditive.

INTRODUCTION

The combination of VCR3 with MTX or other antitumor agents has been widely used for the treatment of various types of malignant diseases in humans. The administration of VCR prior to or together with MTX enhanced the steady level of intracellular MTX and decreased the efflux of MTX in animal and human tumor cells (1-6). VCR was also reported to enhance intracellular polyglutamate formation of MTX (7). These biochemical observations favor the administration of VCR prior to or simultaneously with MTX in patients with cancer. Indeed, therapeutic synergism was reported with this combination for the treatment of mice bearing L1210 leukemia (6). On the basis of these observations, administration of VCR prior to high-dose MTX was incorporated into clinical protocols (8, 9). In further studies, however, other investigators failed to demonstrate the therapeutic synergism of the VCR-MTX combination when simultaneously or sequentially administered in this order using the same L1210 system (2, 10, 11). Therefore, the therapeutic advantage of the VCR-MTX combination is at best controversial.

To evaluate the effect of drug combinations in both in vivo and in vitro studies, the concepts of synergy, additivity, and antagonism have been widely used. However, the concept of additivity which is the basis of the definition of synergy and antagonism has been used in a less precise manner. Workers have simply added the effects of the constituents used separately. Synergy, additivity, and antagonism were then deemed to be present if the effect of the drug combinations were, respectively, more than equal to or less than the sum of the effects of the constituents. If the dose-response curves of two agents follow closely to first-order kinetics, the drug combination can be evaluated by this method. However, dose-response curves do not always follow first-order kinetics, and in such cases the method described above is not suitable for the evaluation of the effect of drug combinations (12-16). To solve the problem, Steel (14, 15) proposed a method for analyzing the effects of combined radiotherapy-chemotherapy with nonlinear dose-response curves. We applied this method for the evaluation of the effects of the VCR combination with MTX and other antitumor agents in vitro.

After the present work was completed (17), we came across a newer analysis for the combined effects of 2 drugs, median effect plot analysis, developed by Chou and Talalay and increasingly used in recent years (18-20). A portion of our data were reanalyzed using this new concept.

MATERIALS AND METHODS

Cell Line

A human acute lymphoblastic leukemia cell line, MOLT-3 (21), was maintained as a suspension in culture flasks (No. 3024; Falcon Plastics, Oxnard, CA) containing RPMI-1640 medium (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated FBS (GIBCO), Grand Island, NY) and antibiotics [penicillin (100 U/ml) and streptomycin (100 µg/ml); Charles Pfizer, Brooklyn, NY].

Chemotherapeutic Agents

VCR sulfate and VLB sulfate were obtained from Eli Lilly, Indianapolis, IN; MTX, Lederle Laboratories, Pearl River, NY; DNR, Farmitalia, Milan, Italy; ara-C, Upjohn, Kalamazoo, MI; BLEO sulfate, Bristol Laboratories, Syracuse, NY; ASN-ase, Merck Sharp & Dohme, West Point, PA; and TMQ through the National Cancer Institute, Bethesda, MD.

Cell Growth Inhibition by Combined Chemotherapeutic Agents

Biological effects of the drugs were evaluated by cell growth inhibition assay (22, 23). Logarithmically growing cells were harvested from the medium and resuspended to a final concentration of 1 x 10^6 cells/ml of fresh medium.

For the continuous mode of exposure to 2 drugs, cell suspensions...
were dispensed (1 ml) into individual wells of a 24-well tissue culture plate with lid (No. 3047; Falcon). Each drug solution at different concentrations was added (10 µl) to individual wells containing cell suspensions. The plates were then incubated in a humidified atmosphere of 95% air/5% CO2 at 37°C for 72 h.

For the short-term mode of exposure, the cell suspensions were dispensed into tissue culture tubes (No. 3033; Falcon) and exposed to 2 drugs with various concentrations in 95% air/5% CO2 at 37°C for 5 h. At the end of incubation, the cells were washed twice with fresh medium with 2% FBS and were resuspended in fresh medium plus 10% FBS. The cell suspensions were then incubated for 0, 3, 8, and 24 h. At the end of the incubation period, the cells were exposed to the second drug for 5 h, washed twice, and resuspended to the same volume of RPMI-1640 medium with 10% FBS. The cell suspensions were again incubated further for 72 h. Viable cell growth was determined by the trypan blue exclusion method. The dose-response curve was plotted on a semilog scale as a percentage of control, the cell number of which was obtained from samples with no drug exposure, but processed simultaneously.

The experiments were carried out in duplicate and repeated twice or more.

**Isobologram Analyses**

Analyses of drug interactions were performed by constructing "an envelope of additivity" (14, 15) on an isobologram as described previously (22). Based on available dose-response curves, we analyzed the combined effect of 2 drugs at the point of ID80. Three isoeffect curves were drawn as follows.

**Mode I Line.** When the dose of Drug A is chosen there remains an increment in effect to be produced by Drug B. If 2 drugs were to act independently, the addition is performed by taking the increment in doses, starting from zero, that give log survivals which add up to ID80.

**Mode II (A) Line.** When the dose of Drug A is chosen, an isoeffect curve can also be calculated by taking the dose increment of Drug B that gives the required contribution to the total effect up to the limit, in this case, ID80.

**Mode II (B) Line.** Similarly, when the dose of Drug B is chosen, an isoeffect curve can be calculated by taking the dose increment of Drug A that gives the required contribution to ID80.

When the dose-response curve of Drug A follows first-order kinetics, Mode II (B) line will be identical to Mode I line, and vice versa. When both drugs follow first-order kinetics all three isoeffect lines will converge to make a straight line connecting 1.0 of the ordinate and abscissa.

The total area enclosed by these 3 lines conceivably represents additive response or an envelope of additivity (Fig. 1).

With combinations of graded doses of Drug A and a chosen dose of Drug B, a single dose-response curve can be drawn. When the experimental ID80 concentration in this combination falls left of the envelope (Fig. 1, Point Pa), the 2 drugs have supraadditive interaction. When the experimental data point is within the envelope, this combination is considered to be noninteractive (additive) (Fig. 1, Point Pb). When this point is in the area right of the envelope, but within the square produced by 1.0 of the ordinate and abscissa, the drugs have subadditive interaction (Fig. 1, Point Pc). When the point is outside the square, both drugs are considered to be mutually protective (Fig. 1, Point Pd).

We find that isoeffect curves had a reasonable amount of variation from experiment to experiment when repeated. We chose to present a representative isobologram after confirmation that, in repeated experiments, individual combination data points were reproducibly in the same area of supraadditivity, additivity, or subadditivity irrespective of the envelope being lean or obese.

**Median Effect Plot Analyses**

The combined effects of 2 drugs in terms of synergism, summation, or antagonism can also be analyzed by the median effect plot (18-20). If the observed effect of 2 drugs acting simultaneously is larger or smaller than that calculated from the product expression, it is assumed that synergism or antagonism, respectively, has occurred. This method involves plotting dose-effect curves for each drug and for one or more multiple-dilution combinations of the drugs using the "median effect" equation

$$\frac{fa}{fu} = (D/D_m)^{a}$$

where D is the dose, Dm is the dose required for 50% effect (e.g., 50% inhibition of cell growth at 72 h as compared to drug-free control), fa is the fraction affected by the dose D, fu is the fraction unaffected, and m is a coefficient signifying the sigmoidicity of the dose-effect curve. The dose-effect curve was plotted using a logarithmic conversion of this equation which determines the m and Dm values. Based on the slope of the dose-effect curves, it can be decided whether the agents have mutually exclusive effects (e.g., similar mode of action) or mutually nonexclusive effects (e.g., independent mode of action). A CI was then determined using the equation

$$CI = \frac{(D_1 h)}{(D_1 h)} + \frac{(D_2 h)}{(D_2 h)} + \alpha\frac{(D_1 h)(D_2 h)}{(D_1 h)(D_2 h)}$$

where (D1h) is the dose of Drug 1 required to produce x% effect alone. (D2h) for x% cell kill can be determined by drawing a least-square regression line on a computer graphic system (19). (D1) is the dose of that drug required to produce the same x% effect in combination with (D2). Similarly, (D2h) is the dose of Drug 2 required to produce x% effect alone, and (D1h) is the dose required to produce the same effect in combination. If the drugs are mutually exclusive, then α is 0; if mutually nonexclusive, then α is 1. When CI = 1, the interaction is considered additive; when CI < 1, synergism is indicated, and when CI > 1, antagonism is indicated. Using this method, we analyzed the data presented in Fig. 3 below.

**RESULTS**

**VCR-MTX Combination.** For the simultaneous and continuous exposure of cells to VCR and MTX, the data points fell on the right side of the envelope (Fig. 2A). Certain data points were in the area of supraadditivity, and others were in the area of subadditivity, and others were in the area of protection. These observations can be interpreted to show that simultaneous exposure to VCR and MTX produced additive or mutually protective interactions. The combination of VCR exposure for 5 h followed by continuous exposure to MTX (Fig. 2B) or simultaneous 5-h exposures to VCR and MTX (Fig. 2C) produced similar interactions, subadditivity and pro-
VCR AND MTX IN COMBINATION IN VITRO

Fig. 2. Isobologram of VCR in combination with MTX. A, continuous and simultaneous exposure to VCR and MTX; B, short-term exposure (5 h) to VCR followed by continuous exposure to MTX; C, short-term, simultaneous exposure to VCR and MTX; D, short-term exposure to VCR followed by short-term exposure to MTX without interval; E, same as in D except with a 3-h interval; F, same as in D except with an 8-h interval; G, same as in D except with a 24-h interval; H, short-term exposure to MTX followed by short-term exposure to VCR without interval; I, same as in H except with a 3-h interval; J, same as in H except with an 8-h interval; K, same as in H except with a 24-h interval.

Fig. 3. Dose-response curves in VCR-MTX combination. A, short-term (5 h) simultaneous exposure to VCR and MTX; B, short-term exposure to MTX followed by short-term exposure to VCR with a 3-h interval; C, short-term exposure to MTX followed by short-term exposure to VCR with a 24-h interval. MTX concentrations (M) for each symbol are shown in . VCR concentrations (M) in the abscissa are to be divided by 10^4 to give the actual value studied.

Examples of the dose-response curve, which were the basis for constructing an isobologram of subadditivity (Fig. 2C), additivity (Fig. 2I), and supraadditivity (Fig. 2K), are shown in Fig. 3, A, B, and C, respectively.

VCR-DNR Combination. Simultaneous and continuous exposure to VCR and DNR produced subadditive effects (Fig. 4A). The effects of simultaneous 5-h exposure to the 2 drugs were subadditive or mutually protective (Fig. 4A). Sequential exposure to 2 drugs with a 24-h interval produced essentially identical interactions whether VCR preceded DNR or vice versa (Fig. 4, C and D).

VCR-ara-C Combination. The simultaneous continuous or simultaneous 5-h exposure to VCR and ara-C resulted in subadditive or protective interaction (Fig. 4, E and F). Five-h exposure to VCR followed by 5-h exposure to ara-C with the interval of 24 h produced the combination data points within the envelope of additivity (Fig. 4G). The reversed order of exposure in similar experiments moved the data points into the area of marginal subadditivity, not far from additivity (Fig. 4I).

VCR Combination with TMQ, VLB, ASN-ase, or BLEO. All the studies were done as simultaneous and continuous exposure to 2 drugs. VCR combinations with TMQ (Fig. 5A) or BLEO (Fig. 5D) were subadditive and protective, while VCR combinations with VLB (Fig. 5B) and ASN-ase (Fig. 5C) tended to be supraadditive, albeit, again not far from the area of additivity.

Median Effect Plot Analysis. In order to evaluate the relat-
DISCUSSION

Linguistically speaking, supraadditivity, additivity, subadditivity, and mutually protective interaction used by Steel should correspond to a more common terminology of synergism, summation, antagonism, and strong antagonism, respectively, used by Chou. Since analytical methods and definitions used by these 2 workers are different, however, results obtained by these 2 methods do not necessarily fall within each respective category. Accordingly, we used each word as defined and used by the 2 respective workers. We observed that data obtained by the 2 methods gave a reasonable degree of proximity in judging synergism, summation, and antagonism.

Our studies show that the inhibitory effects of VCR in combination with MTX are schedule dependent. Exposure to VCR prior to or together with MTX resulted in subadditive and protective interactions (antagonism), indicating that the effects of the 2 drugs in combination are less than those obtained when either drug is used alone. Only the sequence of MTX exposure first followed by VCR, with sufficient intervals, was supraadditive (synergistic). Progressively stronger synergism of this sequence with increasing interval was confirmed by the median effect plot analysis. Our in vitro observations are consistent with reports by Chello et al. that delay of VCR administration for 24 h after MTX did produce increased survival in mice bearing L1210 leukemia (10, 11).

As the biochemical rationale of the VCR-MTX combination, VCR-induced enhancement of steady-state levels of intracellular MTX, decreased MTX efflux, and increased intracellular MTX polyglutamation were described (1-7). These reports are in contrast to observations made by Bruckner et al. who reported suppressive effects of VCR on MTX-induced inhibition of DNA synthesis (24). Our data are consistent with the findings of Bruckner et al.

The reasons why exposure to MTX followed by VCR produced synergistic interaction cannot readily be explained. No biochemical data are available as to whether MTX enhances...
VCR and MTX in Combination In Vitro

Table 1 Median effect plot analysis of data presented in Fig. 3

Data values for the combination are presented as $\alpha$ (fractional inhibition), CI for mutually nonexclusive assumption, and CI for mutually exclusive assumption, numbered in parentheses in this order.

<table>
<thead>
<tr>
<th>MTX ($\times 10^{-8}$ M)</th>
<th>VCR ($\times 10^{-8}$ M)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>5</th>
<th>10</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.2</td>
<td>0.39</td>
<td>0.59</td>
<td>0.69</td>
<td>0.85</td>
<td>0.98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>0.12*</td>
<td>0.37</td>
<td>0.55</td>
<td>0.65</td>
<td>0.80</td>
<td>0.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.0</td>
<td>0.40</td>
<td>0.39</td>
<td>0.50</td>
<td>0.61</td>
<td>0.68</td>
<td>0.83</td>
<td>0.97</td>
<td></td>
</tr>
<tr>
<td>3.0</td>
<td>0.70</td>
<td>0.69</td>
<td>0.72</td>
<td>0.78</td>
<td>0.84</td>
<td>0.89</td>
<td>0.98*</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0.86</td>
<td>0.87</td>
<td>0.88</td>
<td>0.90</td>
<td>0.91</td>
<td>0.928</td>
<td>0.985</td>
<td></td>
</tr>
</tbody>
</table>

* Numbers with underscore, antagonistic interactions.

VCR uptake and/or binding of VCR to microtubules.

We find simultaneous exposure of VCR-MTX, VCR-ara-C, and VCR-BLEO, all of which are a part of clinically active multidrug combinations, to be not more than additive in vitro. The VCR-DNR combination was shown to be subadditive and mutually protective in vitro, whereas the same combination was reported to be therapeutically synergistic in mice bearing L1210 leukemia and in rats bearing L5222 leukemia (25, 26). Furthermore, while our study tends to show that somewhat supradditive interaction of VCR-ASN-ase in vitro, this combination was reported to be clinically more neurotoxic (27). Possible explanations for the discrepancy between in vivo and in vitro data include: (a) target cells are different in each experimental system; (b) data from in vivo experiments take into account both therapeutic and toxic effects, while data from in vitro experiments at the cellular level give effects that will be either therapeutic or toxic depending upon the target cells used; (c) pharmacokinetic values are different between in vivo and in vitro. 

**Note:** Numbers in bold face, synergistic interactions.
vivito conditions; (d) different methods are used for analyzing drug combinations (28, 29); and (e) different definitions of synergism and antagonism are used.

We find clinically active drug combinations do not necessarily produce supraadditivity or synergism in vitro. Conversely, synergistic combination in vitro may not always be therapeutically more efficacious. Nevertheless, our in vitro observations of supraadditivity (synergism) with the sequence of MTX followed by VCR, supported by experimental animal data (10, 11), favor the exploration of this sequence for the treatment of VCR- and MTX-sensitive human neoplasms. Similarly, VCR plus VLB may at least be additive when combined. Neuropathy is the most frequent and dose-limiting toxicity of VCR, whereas the dose-limiting toxicity of VBL is myelosuppression. The combination of VCR and VLB is tempting whether it lessens the neurotoxicity or enhances therapeutic efficacy in the treatment of patients with Vinca alkaloid-sensitive neoplasms.

ACKNOWLEDGMENTS

We thank Dr. Ting-Chao Chou for helpful discussions and critical advice during the analysis of the data.

REFERENCES

Cancer Research


Effects of Vincristine in Combination with Methotrexate and Other Antitumor Agents in Human Acute Lymphoblastic Leukemia Cells in Culture

Yasuhiko Kano, Takao Ohnuma, Tsuyoshi Okano, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/48/2/351

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.